| Direct medical costs of obesity in the United States and the most populous states J Cawley, A Biener, C Meyerhoefer, Y Ding, T Zvenyach, BG Smolarz, ... Journal of Managed Care & Specialty Pharmacy 27 (3), 354-366, 2021 | 376 | 2021 |
| Job Absenteeism Costs of Obesity in the United States: National and State-Level Estimates. J Cawley, A Biener, C Meyerhoefer, Y Ding, T Zvenyach, BG Smolarz, ... Journal of Occupational and Environmental Medicine, 2021 | 32 | 2021 |
| Economic value of nonsurgical weight loss in adults with obesity Y Ding, X Fan, CM Blanchette, BG Smolarz, W Weng, A Ramasamy Journal of Managed Care & Specialty Pharmacy 27 (1), 37-50, 2021 | 20 | 2021 |
| Improvements in health-related quality of life for patients treated with LentiGlobin for sickle cell disease (bb1111) gene therapy J Kanter, JF Tisdale, MY Mapara, JL Kwiatkowski, L Krishnamurti, R Chen, ... Blood 136, 10, 2020 | 8 | 2020 |
| Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN) L Guo, L Li, Q Yu, N Wang, J Chen, Z Wang, Y Ding Diabetes Therapy 13 (6), 1231-1244, 2022 | 3 | 2022 |
| THE IMPACT OF DENOSUMAB COMPARED WITH OTHER OSTEOPOROSIS TREATMENTS ON DIABETES Y Ding, J McCombs Value in Health 19 (3), A199, 2016 | 3 | 2016 |
| Impact of Prophylaxis Usage on Bleeding Rates Among Persons with Hemophilia A: Evidence from Longitudinal Analyses in the USA MB Nichol, R Curtis, Y Ding, ER Aliyev, MA Koerper, M Lou, MM Ullman, ... Blood 132 (Supplement 1), 494-494, 2018 | 1 | 2018 |
| Impact of pain on health-related quality of life in persons with hemophilia from the hemophilia utilization group studies part VI (HUGS VI): USA experience J Wu, M Lou, B Riske, M Ullman, J Baker, R Curtis, M Koerper, J Su, ... HAEMOPHILIA 24, 176-176, 2018 | 1 | 2018 |
| Cost-Effectiveness Comparison Of Denosumab And Zoledronic Acid In The Treatment Of Postmenopausal Osteoporosis Y Ding, J Hay Value in Health 17 (3), A47, 2014 | 1 | 2014 |
| Improvements in health-related quality of life for patients treated with LentiGlobin for sickle cell disease (bb1111) gene therapy Blood 136 (suppl 1), 2020 | | 2020 |
| PRO53 CLOTTING FACTOR UTILIZATION AND BLEEDING RATES AMONG PERSONS WITH HEMOPHILIA A FROM A LONGITUDINAL STUDY R Curtis, Y Ding, ER Aliyev, J Wu, MA Koerper, M Lou, MM Ullman, ... Value in Health 22, S345, 2019 | | 2019 |
| Cost of Wastage for Prophylaxis with FVIII Products Versus Emicizumab in Severe Hemophilia A Patients JS Nanxin (Nick) Li, Yuchen Ding, Benjamine Hagberg Journal of Managed Care & Specialty Pharmacy, 2018 | | 2018 |
| Characterization of Health Outcomes in Patients with Hemophilia A and B: Findings from Psychometric and Health Economic Analyses Y Ding University of Southern California, 2018 | | 2018 |
| VARIATION IN DEMAND RESPONSE TO FDA SAFETY ALERTS N Ning, Y Lu, L Gascue, Y Ding, G Joyce Value in Health 19 (3), A265, 2016 | | 2016 |
| Disparites in Patient Response to Potential Adverse Drug Effects Y Lu, N Ning, L Gascue, Y Ding, G Joyce 2015 Annual Research Meeting, 2015 | | 2015 |
| Disparites in patient response to potential adverse Drug effect N Ning, Y Lu, L Gascue, Y Ding, G Joyce Value in Health 18 (3), A72, 2015 | | 2015 |
| Utilization of Antidiabetics After Fda Safety Announcements Y Ding, L Gascue, Y Lu, N Ning, G Joyce Value in Health 18 (3), A2, 2015 | | 2015 |
| The Job Absenteeism Costs of Obesity in the US J Cawley, A Biener, C Meyerhoefer, Y Ding, T Zvenyach, BG Smolarz, ... 2020 Virtual Annual Research Meeting, 0 | | |
